International Survey of Acute Coronavirus Syndromes-COVID-19
- Conditions
- COVID-19
- Interventions
- Combination Product: Observational (registry)
- Registration Number
- NCT05188612
- Lead Sponsor
- University of Bologna
- Brief Summary
In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.
- Detailed Description
To address existing gaps in knowledge on CVD among European countries at different income levels, a collaboration of outcomes-oriented researchers from the University of Bologna partnered with Central and East European (CEE) countries researchers to conduct the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) investigating underlying threats in patients' CVD health status (NCT01218776).
In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.
Scientific and clinical evidence is evolving on the effects of COVID-19, which can affect multiple organ systems. As, so the COVID-19 pandemic underscores the urgent need for coordination, collaboration, and information-sharing among researchers worldwide. Researchers of many disciplines have, therefore, joined the ISACS-TC investigators to build a multi-disciplinary registry investigating the impact of COVID-19.
Projects should be mainly focused on topics related to:
1. The impact of COVID-19 infection on patients who have attended any health care center (within hospital beds), and who have been discharged or have died at the time of the evaluation. The main objective of this task is to carefully characterize the clinical profile of patients infected with COVID-19 in order to develop a simple prognostic clinical score allowing rapid logistic decision making such as discharge with follow-up, referral to provisional hospitals, or admission to hospital centers with advanced equipment or specialized procedures and techniques. A secondary objective of this retrospective analysis is to evaluate the risk-adjusted influence of prior evidence-based treatments and comorbidities on patients infected with the disease.
2. The second issue relates to the long-term health consequences after COVID-19 infection. Early reports suggest residual effects of SARS-CoV-2 infection, such as fatigue, dyspnea, chest pain, cognitive disturbances, arthralgia, and decline in quality of life. However, the evidence is still scarce. Prior studies did not take into account the vast majority of patients with a mild course of the infection. As well, the definition of the post-acute COVID-19 timeline is evolving. Today we may summarize the post-acute COVID-19 syndrome into two categories:
* subacute or ongoing symptomatic COVID-19, which includes symptoms and abnormalities present from 4-12 weeks beyond acute COVID-19;
* chronic or post-COVID-19 syndrome, which includes symptoms and abnormalities persisting or present beyond 12 weeks of the onset of acute COVID-19 and not attributable to alternative diagnoses. Systematic study of sequelae after recovery from acute COVID-19 is needed to develop an evidence-based multidisciplinary team approach for caring for these patients, and to inform research priorities.
One trained physician will critically review the patients' reported symptoms and will assess SARS-CoV-2 IgG at each visit. In addition, wherever needed, the investigators will investigate the daily living status of survivors of COVID-19 using telephone interview questionnaires including Activity Daily Living (ADL), Self-rating Depression Scale (SDS), and New York Heart Association (NYHA) functional class.
* Sponsor: Raffaele Bugiardini (Principal Investigator; PI) - University of Bologna
* Co-PI Investigator (Clinical Research): Olivia Manfrini (University of Bologna)
* Co-PI Investigator (Translational Research): Lina Badimon (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)
* Collaborator: Associazione Per La Ricerca Cardiologica, Roma
National Investigators:
Bosnia and Herzegovina: Local PI: Mirza Dilic (Clinical Center University of Sarajevo)
Croatia: Local PI: Davor Miličić (University Hospital Center Zagreb)
Other Investigators:
* Marijan Pašalić (University Hospital Center Zagreb)
* Petra Mjehović (University Hospital Center Zagreb)
Italy: Local PI: Stefano Nava (University of Bologna)
Other Investigators:
* Gaetano Caramori (University of Messina)
* Antonio David, (University of Messina)
* Giuseppe Mancuso (University of Messina)
* Maria Laura Vega Pitao (University of Bologna)
* Giulia Panzuti (University of Bologna)
* Edina Cenko (University of Bologna)
* Maria Bergami (University of Bologna)
* Marialuisa Scarpone (University of Bologna)
* Antonio Spanevello (IRCCS Maugeri)
* Fabio Angeli (IRCCS Maugeri)
* Dina Visca (IRCCS Maugeri)
* Martina Zappa (IRCCS Maugeri)
* Paolo Emilio Puddu (Associazione Per La Ricerca Cardiologica, Roma)
Macedonia: Local PI: Sasko Kedev and Marija Vavlukis (University "Ss. Cyril and Methodius")
Other Investigators:
* Lidija Poposka (University Clinic of Cardiology)
* Milena Stefanovic (University Clinic of Infectious Diseases)
* Ilir Demiri (University Clinic of Infectious Diseases) Romania: Local PI: Maria Dorobantu (Emergency Clinical Hospital of Bucharest) Other Investigators: Oana Fronea Gheorghe (Emergency Clinical Hospital of Bucharest)
Serbia: Local PI: Marija Zdravkovic (Hospital Medical Center Bezanijska kosa, Belgrade), Zorana Vasiljevic (University of Belgrade)
Other Investigators:
* Nebojsa Ladjevic, Clinic for Anesthesia, Covid Hospital Batajnica, Belgrade
* Radmilo Jankovic (Clinical Center Nis)
* Goran Loncar (Institute for Cardiovascular Diseases Dedinje)
* Ratko Lasica (Clinical Center of Serbia)
* Miodrag Petrović (Institute for Cardiovascular Diseases Sremska Kamenica, Novi Sad)
* Vlada Vukomanovic (Clinical Hospital Center Dragiša Mišković Belgrade)
* Dubravka Rajic (Clinical Center of Serbia)
* Ana Uscumlic (Clinical Center of Serbia)
* Sanja Stankovic (Clinical Center of Serbia)
Spain: Local PI: Teresa Padro (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)
Other Investigators:
* Guiomar Mendieta ( CNIC, Madrid)
* Rosa Suades (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)
* Gemma Vilahur (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)
United Kingdom: Local PI: Charalambos Antoniades (Oxford University)
Other Investigators:
* Maria Lyasheva (University of Oxford)
* Lucy Kingham (University of Oxford)
* Christos Kotanidis (University of Oxford)
* Cheng Xie (University of Oxford)
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 10000
- Age ≥18 years (male or female)
- Patients admitted to any hospital center with a confirmed diagnosis of COVID-19 infection.
• Underage or not able to give informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Dyslipidemias Observational (registry) Non-interventional patient registry Smoking Observational (registry) Non-interventional patient registry Kidney Disease Observational (registry) Non-interventional patient registry Vascular diseases Observational (registry) Non-interventional patient registry Female Observational (registry) Non-interventional patient registry Elderly Observational (registry) Non-interventional patient registry Diabetes Observational (registry) Non-interventional patient registry Male Observational (registry) Non-interventional patient registry Hypertension Observational (registry) Non-interventional patient registry Heart Diseases Observational (registry) Non-interventional patient registry
- Primary Outcome Measures
Name Time Method Death all cause 12-month Occurrence of all cause death
- Secondary Outcome Measures
Name Time Method Sepsis 30 day, 6 -12 months Occurrence of sepsis (According to the attending physician)
Pneumonia 30 day, 6 -12 months Occurrence of pneumonia (According to the attending physician)
Clinically relevant bleeding 30 day, 6 -12 months Occurrence of clinically relevant bleeding (According to the attending physician)
Thrombosis (arterial, venous) 30 day, 6 -12 months Occurrence of thrombosis and thromboembolism (According to the attending physician)
Heart failure 30 day, 6 -12 months Occurrence of heart failure or worsening of preexisting heart failure (According to the attending physician)
Worsening renal function 30 day, 6 -12 months Occurrence of kidney disease or worsening of preexisting kidney failure (According to the attending physician)
Respiratory Insufficiency 30 day, 6 -12 months Occurrence of respiratory insufficiency or worsening of preexisting respiratory insufficiency (According to the attending physician)
Systemic Inflammatory Response Syndrome (SIRS) 30 day, 6 -12 months Occurrence of SIRS (According to the attending physician)
Activity Daily Living status 30 day, 6 -12 months (According to the attending physician)
Depression status 30 day, 6 -12 months (According to the attending physician)
Trial Locations
- Locations (2)
University of Bologna
🇮🇹Bologna, Italy
IR-Hospital de la Santa Creu i Sant Pau, UAB
🇪🇸Barcelona, Spain